Diagnostic Accuracy of MRI, DWI MRI, FDG-PET/CT and FEC PET/CT in the Detection of Lymph Node Metastases in Surgically Staged Endometrial and Cervical Carcinoma

Endometrial Cancer Clinical Trial

— MAPPING  

Official title:

Diagnostic Accuracy of MRI, Diffusion-weighted MRI, FDG-PET/CT and Fluoro-ethyl-choline PET/CT in the Detection of Lymph Node Metastases in Surgically Staged Endometrial and Cervical Carcinoma

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01836484
• Other study ID #: 007697
• Status: Completed
• Start date: June 2012
• Est. completion date: December 2018

Study information

• Verified date: February 2020
• Source: Barts & The London NHS Trust
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This is a prospective diagnostic performance study which compares three new imaging methods with the current standard imaging method for the diagnosis of metastatic lymph nodes.

Description:

The aim is to demonstrate whether leading edge molecular imaging technologies (FDG-PET/CT, DW-MRI and Fluoro-ethyl-choline (FEC) PET/CT) can identify lymph node metastases with sufficient accuracy to allow non-invasive lymph node staging in patients with endometrial and cervical carcinoma.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 162
• Est. completion date: December 2018
• Est. primary completion date: December 2018
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Females 18 years or older; (no upper limit).

2. Patients with histologically confirmed cancer of the cervix or endometrium.

1. In patient with cervix cancer, there must be confirmation of invasive disease; FIGO stage 1B1 or higher FIGO stage demonstrated clinically and/or on MRI. In patients with advanced disease being considered for chemoradiotherapy treatment, patients may be considered for entry if nodal lymphadenectomy is being used to inform radiotherapy planning;

2. In patients with endometrial cancer, a) stage 1A with myometrial invasion or any higher stage and grade 3 b) stage 1A with myometrial invasion or any other higher stage and serous papillary or clear cell sub-types

3. stage II disease or above and any histology grade The MDT decision may be based on the combination of tumour characteristics on histology, clinical and imaging findings.

3. No contra-indication to FDG-PET/CT, FEC-PET/CT or MRI.

4. Fit for surgical lymphadenectomy, as determined by the local MDT. The patient should also be considered fit for extended field radiotherapy in cases where lymphadenectomy is being undertaken to inform radiotherapy planning.

The extent of lymph node dissection will be made by the local multidisciplinary team, based on the presence of risk factors for lymph node metastases, according to the protocol. Patients must be considered fit to undergo lymph node dissection.

5. Able and willing to give written informed consent and to comply with the study protocol procedures

Exclusion Criteria:

1. Known contra-indication to MRI or PET/CT scan.

2. Known allergy to FDG or FEC.

3. Not considered fit for lymphadenectomy (open or laparoscopic) or, where appropriate, radiotherapy, as determined by the local MDT.

4. If the patient is pregnant or breast-feeding.

5. Females of childbearing potential must be willing to use an effective method of contraception (hormonal or barrier method of birth control) from the time consent is signed until 6 weeks after the last PET/CT scan unless undergoing hysterectomy.

Note: subjects are not considered of childbearing potential if they are surgically sterile (they have undergone bilateral tubal ligation or bilateral oophorectomy) or they are postmenopausal

6. Females of childbearing potential must have a negative pregnancy test within three weeks prior to being registered for the study.

7. Participation in another Clinical Trial of an Investigational Medicinal Product (CTIMP). If patient's have recently completed a CTIMP trial they must have had their last dose(s) of study drug prior to their first imaging procedure on the MAPPING study.

8. Participation in another clinical trial (CTIMP or non-CTIMP) where the protocol contains imaging procedures that would occur during the MAPPING study.

9. Medical or psychiatric illness, which makes the patient unsuitable or unable to give informed consent.

Related Conditions & MeSH terms

• Carcinoma
• Cervical Cancer: Invasive Disease, FIGO Stage 1B1 or Higher
• Endometrial Cancer
• Endometrial Neoplasms
• Stage 1A With Myometrial Invasion or Any Higher Stage and Grade 3
• Stage 1A With Myometrial Invasion or Any Other Higher Stage and Serous Papillary or Clear Cell Sub-types
• Stage II Disease or Above and Any Histology Grade
• Surgically Staged Endometrial and Cervical Carcinoma

Intervention

Diagnostic Test:
• Diffusion-weighted MRI

• Fluorodeoxyglucose-18-PET/CT

• Fluoro-ethyl-coline-PET/CT

Locations

Country	Name	City	State
United Kingdom	Birmingham City Hospital, Sandwell & West Birmingham Hospitals NHS Trust	Birmingham
United Kingdom	Queen Elizabeth Hospital, Birmingham University Hospitals, Birmingham NHS Foundation Trust	Birmingham
United Kingdom	Hammersmith Hospital, Imperial College Healthcare NHS Trust	London
United Kingdom	St Bartholomew's Hospital, Barts Health NHS Trust	London
United Kingdom	University College London Hospital	London
United Kingdom	Royal Preston Hospital, Lancashire Teaching Hospitals NHS Foundation Trust	Preston
United Kingdom	The Royal Marsden, The Royal Marsden NHS Foundation Trust	Sutton

Sponsors (10)

Lead Sponsor	Collaborator
Barts & The London NHS Trust	Birmingham Women's NHS Foundation Trust, Case Western Reserve University, Guy's and St Thomas' NHS Foundation Trust, Hammersmith Hospitals NHS Trust, Memorial Sloan-Kettering Cancer Center, USA, Queen Elizabeth Hospital, Gateshead, UK, Royal Marsden NHS Foundation Trust, Royal Preston Hospital, Lancashire, UK, University of Birmingham

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Detection rate (DR) vrs false positive rate (FPR) for each of the diagnostic modalities.		36 months
Secondary	Detection rate (DR) vrs false positive rate (FPR) between each of the diagnostic modalities and within different histological sub-sets.		36 months
Secondary	Nodal Coverage planning: standard radiotherapy planning vrs DW-MRI		36 months
Secondary	Histopathological findings vrs functional imaging findings		36 months

External Links

•   CancerHelp - MAPPING